Why the study?
Is a second season of palivizumab prophylaxis safe and immunogenic in children who previously received it?
Is a second season of palivizumab prophylaxis safe and immunogenic in children who previously received it?
A second season of palivizumab prophylaxis is safe and well-tolerated in children, without significant immunogenicity concerns.
Answers are grounded in this paper and cite their sources.
Supports tolerability of second-year palivizumab without significant immunogenicity; leaves open need for prospective trials to guide practice.
To evaluate the safety and immunogenicity of palivizumab, 55 children who received palivizumab in the IMpact-RSV trial received 5 monthly doses of 15 mg/kg palivizumab (Synagis) during the subsequent year. The single child with an antipalivizumab titer of >1/40 had no associated serious adverse events and had expected serum palivizumab trough concentrations. Second year palivizumab prophylaxis was safe and well-tolerated.
No takes yet. Share an insight, caveat, or question.
Null et al. (2005) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: